The key to combating AIDS in Russia may be to treat HIV-infected drug users. A new model estimating the spread of HIV in Russia suggests that treating injection drug users with antiretroviral medication will slow transmission of the virus among the general population.
Deadly dengue claimed two more lives in the national capital pushing the countrywide death count to 175 as 35 fresh cases poured in taking the number of those afflicted with the mosquito-borne disease to 9,680.
Antiretroviral therapy can keep HIV infection in check and delay and ameliorate the symptoms of HIV/AIDS. However, the drugs do not manage to eradicate the virus completely; individuals have to stay on the drugs permanently. Preclinical studies in mice by Ekatarina Dadachova and colleagues (Albert Einstein College of Medicine) published in the international open-access journal PLoS Medicine now suggest a new strategy to locate and kill many if not all HIV-infected cells in the body.
Researchers at the University of Pennsylvania School of Medicine have discovered how the Kaposi’s sarcoma-associated herpesvirus (KSHV) subverts a normal cell process in order to promote tumor growth. The finding, published in the most recent issue of PLoS Pathogens, offers new potential strategies for treating Kaposi’s sarcoma and other cancers associated with viruses
An estimated 50 million people were affected by zoonotics diseases, including H5N1 (bird flu), SARS and Rabies, between 2000 and 2005 and up to 78,000 died. No effective vaccines exist for the most common diseases. And the Dengue virus, which caused about a third of the deaths is experiencing a global resurgence. Zoonotic diseases can become serious killers if they adapt to human to human transmission — HIV and Measles are two examples.
Mayo Clinic Cancer Center’s Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI) for prostate cancer research has been renewed for an additional five years. SPORE grants are highly competitive awards given to institutions on the cutting edge of translational research in specific types of cancer.
Gene-base therapy may be effective against HIV, U.S. researchers report. An investigational gene-based immunotherapy called VRX496 suggests it can fight the virus, according to a phase I, open-label, non-randomized clinical trial conducted at the University of Pennsylvania School of Medicine.
The American Thoracic Society (ATS) has published a new statement on the pathogenesis, prevention and treatment of liver damage caused by anti-tuberculosis (TB) medications. The statement, which appeared in the October 15 issue of the American Journal of Respiratory and Critical Care Medicine, gives a review of current national and international literature on drug-induced liver injury (DILI) or hepatotoxicity, a potential side effect of more than 700 drugs approved for use in the United States.
Ear infections are among the most common diseases seen in pediatric practice. They have generally been considered bacterial diseases and are therefore usually treated with antibiotics. New research, published in the Dec. 15 issue of Clinical Infectious Diseases and currently available online, provides evidence that viruses are found in a great many ear infection cases and may complicate treatment.
How well an individual’s immune system controls HIV during the earliest phases of infection appears to depend on both the specific versions of key immune-system molecules called HLA Class I that have been inherited, as well as on the fragments of viral protein those molecules display to the T lymphocytes that usually destroy infected cells. In a report in the November issue of PLOS Medicine, researchers from the Partners AIDS Research Center at Massachusetts General Hospital (PARC/MGH) report that specific HLA Class I/HIV viral fragment combinations are associated with a more powerful antiviral response, findings that may help develop vaccines against HIV.